Thibault MesplÃ¨de

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7427718/publications.pdf

Version: 2024-02-01

96	2,793	147726	206029
papers	citations	31 h-index	48 g-index

101	101	101	3126
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. Journal of Virology, 2012, 86, 2696-2705.	1.5	212
2	The E3 Ubiquitin Ligase Triad3A Negatively Regulates the RIG-I/MAVS Signaling Pathway by Targeting TRAF3 for Degradation. PLoS Pathogens, 2009, 5, e1000650.	2.1	159
3	HIV drug resistance against strand transfer integrase inhibitors. Retrovirology, 2017, 14, 36.	0.9	141
4	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology, 2013, 10, 22.	0.9	114
5	Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology, 2018, 15, 56.	0.9	85
6	The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology, 2014, 11, 7.	0.9	74
7	p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes. Journal of Virology, 2012, 86, 94-107.	1.5	71
8	HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. Journal of Infectious Diseases, 2018, 218, 688-697.	1.9	69
9	Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase. Journal of Virology, 2015, 89, 3163-3175.	1.5	66
10	Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases, 2013, 26, 43-49.	1.3	63
11	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. Antimicrobial Agents and Chemotherapy, 2013, 57, 6223-6235.	1.4	62
12	Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2016, 71, 1948-1953.	1.3	61
13	The development of novel HIV integrase inhibitors and the problem of drug resistance. Current Opinion in Virology, 2012, 2, 656-662.	2.6	55
14	Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis. Journal of Virology, 2013, 87, 8110-8123.	1.5	55
15	Transcriptional reâ€programming of primary macrophages reveals distinct apoptotic and antiâ€tumoral functions of IRFâ€3 and IRFâ€7. European Journal of Immunology, 2009, 39, 527-540.	1.6	51
16	Involvement of TBK1 and IKKÎµ in lipopolysaccharide-induced activation of the interferon response in primary human macrophages. European Journal of Immunology, 2007, 37, 528-539.	1.6	49
17	Resistance to HIV integrase inhibitors. Current Opinion in HIV and AIDS, 2012, 7, 401-408.	1.5	49
18	Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. Retrovirology, 2013, 10, 73.	0.9	48

#	Article	IF	Citations
19	Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. Aids, 2014, 28, 813-819.	1.0	48
20	Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. Journal of Antimicrobial Chemotherapy, 2014, 69, 2733-2740.	1.3	47
21	Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses, 2015, 7, 3703-3718.	1.5	45
22	Integrase strand transfer inhibitors in the management of HIV-positive individuals. Annals of Medicine, 2014, 46, 123-129.	1.5	43
23	The antimalarial drug amodiaquine possesses antiâ€ZIKA virus activities. Journal of Medical Virology, 2018, 90, 796-802.	2.5	43
24	What if HIV were unable to develop resistance against a new therapeutic agent?. BMC Medicine, 2013, 11, 249.	2.3	40
25	Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. Journal of Antimicrobial Chemotherapy, 2016, 71, 2083-2088.	1.3	40
26	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. Journal of Infectious Diseases, 2018, 218, 698-706.	1.9	40
27	Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infection, Genetics and Evolution, 2016, 46, 286-291.	1.0	37
28	Antimalarial drugs and their metabolites are potent Zika virus inhibitors. Journal of Medical Virology, 2019, 91, 1182-1190.	2.5	36
29	Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?. Viruses, 2014, 6, 3377-3385.	1.5	34
30	Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions. Journal of Virology, 2015, 89, 4681-4684.	1.5	33
31	Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	32
32	HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug. Antimicrobial Agents and Chemotherapy, 2012, 56, 4257-4267.	1.4	30
33	The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. Aids, 2016, 30, 2267-2273.	1.0	30
34	Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation. Journal of Virology, 2008, 82, 5735-5749.	1.5	29
35	HIV Drug Resistance and the Advent of Integrase Inhibitors. Current Infectious Disease Reports, 2013, 15, 85-100.	1.3	29
36	IÎºB Kinase Îµ-Dependent Phosphorylation and Degradation of X-Linked Inhibitor of Apoptosis Sensitizes Cells to Virus-Induced Apoptosis. Journal of Virology, 2012, 86, 726-737.	1.5	28

#	Article	IF	Citations
37	Identification of resveratrol analogs as potent antiâ€dengue agents using a cellâ€based assay. Journal of Medical Virology, 2017, 89, 397-407.	2.5	26
38	The latest evidence for possible HIV-1 curative strategies. Drugs in Context, 2018, 7, 1-14.	1.0	26
39	Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors. Journal of Virology, 2014, 88, 9683-9692.	1.5	22
40	Repression by Homeoprotein Pitx1 of Virus-Induced Interferon A Promoters Is Mediated by Physical Interaction and trans Repression of IRF3 and IRF7. Molecular and Cellular Biology, 2002, 22, 7120-7133.	1.1	21
41	Might dolutegravir be part of a functional cure for HIV?. Canadian Journal of Microbiology, 2016, 62, 375-382.	0.8	20
42	M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. Journal of Antimicrobial Chemotherapy, 2017, 72, 3008-3011.	1.3	20
43	Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update. Expert Opinion on Investigational Drugs, 2018, 27, 951-962.	1.9	20
44	Integrase Strand Transfer Inhibitors in HIV Therapy. Infectious Diseases and Therapy, 2013, 2, 83-93.	1.8	19
45	Inhibition of NF-ÎºB-dependent HIV-1 replication by the marine natural product bengamide A. Antiviral Research, 2018, 152, 94-103.	1.9	19
46	Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Journal of Virology, 2015, 89, 10482-10488.	1.5	18
47	Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Research, 2013, 98, 441-448.	1.9	17
48	Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert Opinion on Pharmacotherapy, 2019, 20, 385-397.	0.9	17
49	Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency. Viruses, 2014, 6, 3487-3499.	1.5	16
50	Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 1207-1213.	1.9	16
51	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. Aids, 2015, 29, 1459-1466.	1.0	15
52	The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. Journal of Virology, 2015, 89, 11269-11274.	1.5	15
53	A high-throughput assay for HIV-1 integrase 3â€²-processing activity using time-resolved fluorescence. Journal of Virological Methods, 2012, 184, 34-40.	1.0	14
54	A resveratrol analog termed 3,3â€²,4,4â€²,5,5â€²-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. Journal of Medical Virology, 2015, 87, 2054-2060.	2.5	14

#	Article	IF	Citations
55	The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. Aids, 2015, 29, 2255-2260.	1.0	14
56	Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. PLoS ONE, 2015, 10, e0128310.	1.1	14
57	Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity. Antimicrobial Agents and Chemotherapy, 2015, 59, 2882-2885.	1.4	14
58	The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. MBio, 2017, 8, .	1.8	14
59	Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Drugs in Context, 2020, 9, 1-11.	1.0	14
60	HIV-1 Group O Resistance Against Integrase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 9-15.	0.9	13
61	Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in firstâ€line therapy. Journal of the International AIDS Society, 2015, 18, 20824.	1.2	13
62	Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus. Journal of Natural Products, 2020, 83, 2416-2424.	1.5	12
63	The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir. Antimicrobial Agents and Chemotherapy, 2015, 59, 310-316.	1.4	11
64	Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology, 2016, 13, 31.	0.9	11
65	JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. Journal of Virology, 2017, 91, .	1.5	11
66	Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes. Journal of Virology, 2019, 93, .	1.5	11
67	The POU Transcription Factor Oct-1 Represses Virus-Induced Interferon A Gene Expression. Molecular and Cellular Biology, 2005, 25, 8717-8731.	1.1	10
68	The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. Journal of the International AIDS Society, 2014, 17, 19518.	1.2	10
69	Dolutegravir inhibits HIV-1 Env evolution in primary human cells. Aids, 2015, 29, 659-665.	1.0	10
70	Where are we with injectables against HIV infection and what are the remaining challenges?. Expert Review of Anti-Infective Therapy, 2018, 16, 143-152.	2.0	10
71	Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor. Antiviral Chemistry and Chemotherapy, 2015, 24, 28-38.	0.3	9
72	Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1045-1053.	1.3	9

#	Article	IF	Citations
73	HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase. Antimicrobial Agents and Chemotherapy, 2014, 58, 7141-7150.	1.4	8
74	Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors. Antimicrobial Agents and Chemotherapy, 2015, 59, 1942-1949.	1.4	8
75	Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. AIDS Research and Therapy, 2017, 14, 2.	0.7	8
76	Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. Journal of Antimicrobial Chemotherapy, 2021, 76, 639-647.	1.3	8
77	Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. Journal of Antimicrobial Chemotherapy, 2015, 70, 2810-2815.	1.3	7
78	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. Journal of Antimicrobial Chemotherapy, 2015, 70, 750-756.	1.3	7
79	Early Antiretroviral Therapy Prevents Viral Infection of Monocytes and Inflammation in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	7
80	Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Journal of Virology, 2015, 89, 12002-12013.	1.5	6
81	Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1. Expert Opinion on Investigational Drugs, 2020, 29, 273-283.	1.9	6
82	Will LEDGIN molecules be able to play a role in a cure for HIV infection?. EBioMedicine, 2016, 8, 14-15.	2.7	5
83	Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc. Journal of the International AIDS Society, 2014, 17, 19531.	1.2	4
84	HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. Journal of the International AIDS Society, 2014, 17, 19738.	1.2	4
85	HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity. Journal of Virology, 2017, 91, .	1.5	4
86	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. Antimicrobial Agents and Chemotherapy, 2014, 58, 3580-3580.	1.4	3
87	Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal Antibodies. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 7-14.	0.9	3
88	Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review. Pathogens and Immunity, 2016, 1, 41.	1.4	3
89	Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses. Clinical Infectious Diseases, 2019, 69, 1460-1461.	2.9	2
90	Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice. Journal of Global Antimicrobial Resistance, 2020, 20, 316-317.	0.9	2

#	Article	IF	Citations
91	Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1245-1251.	0.9	2
92	Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout. Aids, 2018, 32, 1773-1780.	1.0	1
93	Reply to Darcis and Berkhout. Journal of Infectious Diseases, 2018, 218, 2020-2021.	1.9	0
94	Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART. PLoS ONE, 2018, 13, e0198090.	1.1	0
95	Reply to Achieng and Riedel. Journal of Infectious Diseases, 2019, 219, 167-169.	1.9	0
96	HIV-1 Resistance to Integrase Inhibitors. , 2017, , 559-564.		0